Topical Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

January 6, 2023

Conditions
Coronary Artery DiseaseValvular Heart DiseaseSurgical Blood Loss
Interventions
DRUG

Tranexamic Acid 100 MG/ML

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage

DRUG

normal saline

Normal saline is a cornerstone of intravenous solutions commonly used in the clinical setting. It is a crystalloid fluid administered via an intravenous solution. Its indications include both adult and pediatric populations as sources of hydration and electrolyte disturbances

Trial Locations (1)

11410

National Cardiovascular Center Harapan Kita, Jakarta

All Listed Sponsors
lead

Indonesia University

OTHER